TABLE 5.
Clinical Characteristics of Gastrectomy, Chemotherapy, and Rate of Unintended Return to Care Over Time After Initiating the MIREC Pathway
| Post-MIREC (May 2016–Dec 2017) (N = 89) |
Post-MIREC (Jan 2018–Mar 2023) (N = 297) |
||||
|---|---|---|---|---|---|
| Characteristic | N | % | N | % | P Value |
| Pre-op chemotherapy received. Yes |
61 | 68.5 | 234 | 78.8 | 0.046 |
| Time between last chemotherapy to gastrectomy (days) Median |
43 | 41 | 0.932 | ||
| Duration of surgery (min) Median |
267 | 233 | 0.001 | ||
| Length of hospital stays(day) Median |
3 | 2 | <0.0001 |
||
| Adherence to MIREC |
68 | 79% | 278 | 94% | 0.003 |
| ER visit 30 days |
23 | 25.8 | 53 | 17.9 | 0.096 |
| Readmission 30 days |
17 | 19.1 | 26 | 8.8 | 0.007 |
| Reoperation 30 days |
8 | 9 | 18 | 6.1 | 0.334 |
| ICU utilization Yes |
3 | 3.4 | 8 | 2.7 | 0.736 |
| Mortality 30 days |
1 | 1.1 | 3 | 1 | 0.926 |
| Time between gastrectomy to restarting chemotherapy (days) Median |
49 |
41 |
0.056 | ||
| Weight changes after gastrectomy (kg) Median |
−6.1 | −5.4 | 0.240 |
||
| Post-op chemotherapy received Yes |
54 | 60.7 | 191 | 64.3 | 0.532 |
ICU indicates intensive care unit; MIREC, minimally invasive recovery and empowerment care.